Table 4

Changes in liver function tests at 24 weeks of the study, according to to the nature and number of comorbidities

HypertensionOverweight/obesityT2DMElevated cholesterol
ALT (U/L)Baseline values50.3±32.852.3±34.753.9±31.051.4±33.4
Change from baseline*−19.7±26.5−21.6±29.4−22.0±22.7−20.8±27.3
AST (U/L)Baseline values44.3±27.345.1±26.646.4±24.944.8±26.8
Change from baseline*−16.9±21.8−17.7±21.6−18.4±19.9−17.1±21.6
GGT (U/L)Baseline values53.7±39.352.6±38.057.7±38.252.3±37.4
Change from baseline*−17.6±31.6−17.9±31.6−18.7±31.2−17.2±30.6
One comorbidityTwo comorbiditiesThree comorbiditiesFour comorbidities
ALT (U/L)Baseline values44.5±30.949.7±33.052.8±34.256.3±33.5
Change from baseline*−18.4±28.1−20.4±28.2−21.2±28.3−22.4±23.9
AST (U/L)Baseline values38.2±20.542.8±23.347.1±30.547.5±25.6
Change from baseline*−14.8±18.2−16.2±19.3−18.7±24.3−17.9±20.3
GGT (U/L)Baseline values47.8±39.048.8±33.656.5±40.757.2±39.7
Change from baseline*−15.7±33.5−15.5±28.4−19.5±32.4−18.6±32.9
  • Data are expressed as mean±SD.

  • *There was a significant decrease in the mean values of the liver function tests (p<0.001 compared with baseline, paired t-test).

  • ALT, alanine aminotransferase; AST, aspartate aminotransferase; GGT, gamma-glutamyl transferase; T2DM, type 2 diabetes mellitus.